S&P 500 Movers: GNW, EW
In early trading on Wednesday, shares of Edwards Lifesciences topped the list of the day's best performing components of the S&P 500 index, trading up 9.3%.
Why Edward Lifesciences (EW) Stock Is Up Today
For the second quarter Edwards Lifesciences reported earnings of 88 cents a share, beating the Capital IQ Consensus Estimate of 77 cents a share by 11 cents.
UPDATE 2-Legal settlement lifts Edwards Lifesciences' profit
Edwards Lifesciences Corp posted stronger second-quarter earnings on Tuesday, propelled by a gain from a legal settlement and higher sales of heart valves that are implanted using a less-invasive procedure than traditional open-heart surgery.
Edwards Lifesciences Reports Strong Second Quarter Results
Edwards Lifesciences Corporation , the global leader in the science of heart valves and hemodynamic monitoring, today reported net income for the quarter ended June 30, 2014 of $547.0 million, or $5.09 per diluted share, and non-GAAP net income of $94.0 million, or $0.88 per diluted share.
Edwards Lifesciences Corp Price Target Increased to $79.00 by Analysts at RBC Capital
The firm currently has a "sector perform" rating on the stock. RBC Capital's price target suggests a potential downside of 6.95% from the stock's previous close.
5 Medical Institutions Identified in Secret Testing in Senate...
Senate Judiciary Committee, Senator Charles Grassley is still "monitoring" an FDA investigation he reopened in 2014 after it was brought to his attention that important documents were withheld from him by Northwestern Memorial Hospital and Northwestern University regarding consent to test the Myxo ETlogix prototype heart valve device in ... (more)
The Motley Fool
Medtronic Sets Pace for Future Growth
The cardiovascular group is the company's largest unit. Medtronic recently resolved long standing patent infringement issues with rival device maker, Edwards Lifesciences Corp .
The Motley Fool
Will Edwards Lifesciences Stock Slip in the Second Half of 2014?
In that time, shares of Edwards have fallen by more than 13% as concerns over the company's sales of its Sapien heart valves have swirled.
Study Explores Expanded Use For Edwards' And Medtronic's New Heart Valves
In the last few years transcatheter aortic valve replacements from Edwards Lifesciences and Medtronic have entered the marketplace and now offer an alternative to surgery for some patients.